Table 1 Cell viability in MCF-7 and SK-Br-3 cells

Trastuzumab (50 μg/ml)

95.35% (± 2.27)

72.58% (± 1.31)

(EGF + T ₅₀ : P < 0.001)

EGF (400 ηg/ml)

101.70% (± 1.84)

81.43% (± 2.46)

(EGF + T ₅₀ : P < 0.001)

EGF (400 ηg/ml) + Trastuzumab (50 μg/ml)

89.52% (± 1.95)

89.40% (± 2.20)

(Trastuzumab ₅₀ : P < 0.05)

HRG (200 ηg/ml)

107.01% (± 2.42)

115.40% (± 2.08)

(Trastuzumab ₅₀ : P < 0.001)

(Trastuzumab ₅₀ : P < 0.001)

HRG (200 ηg/ml) + Trastuzumab (50 μg/ml)

93.76% (±2.52)

114.50% (± 1.98)

(HRG: P < 0.001)

(Trastuzumab ₅₀ : P < 0.001)